Immune checkpoint inhibitor associated myocarditis
Conditions
Interventions
Index test:Troponin T, electrocardiogram, echocardiogram, cardiac MRI
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Pathological diagnosis of malignant tumors; 2. Patients treated with immune checkpoint inhibitors for malignant tumors; 3. Complete drug treatment cycle and follow-up cycle; 4. 18 years old< = age< = 80 years; 5. Have not participated in other drug clinical studies within 1 month and voluntarily accept treatment under this regimen; 6. Termination Event: Cardiac Rehabilitation/Death.
Exclusion criteria
Exclusion criteria: 1. Patients with clear evidence that non-ICIs cause cardiac injury; 2. Serious adverse events other than cardiac side effects during the medication period, resulting in medication termination; 3. Patients with obvious cardiopulmonary, liver and kidney function impairment, accompanied by serious complications, such as coronary heart disease, cerebral infarction, COPD, etc.; 4. Expected survival < 6 months; 5. Data loss during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cTNT; | — |
Countries
China
Contacts
Public ContactCheng Leilei
Zhongshan Hospital, Fudan University
Outcome results
None listed